Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas: Application of the World Health Organization's 2016 Revised Criteria for Central Nervous System Tumors

Jamal H. Carter, Samantha N. McNulty, Patrick J. Cimino, Catherine E. Cottrell, Jonathan W. Heusel, Katinka A. Vigh-Conrad, Eric J. Duncavage

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The 2007 World Health Organization Classification of Tumours of the Central Nervous System classifies lower-grade gliomas [LGGs (grades II to III diffuse gliomas)] morphologically as astrocytomas or oligodendrogliomas, and tumors with unclear ambiguous morphology as oligoastrocytomas. The World Health Organization's newly released (2016) classification incorporates molecular data. A single, targeted next-generation sequencing (NGS) panel was used for detecting single-nucleotide variation and copy number variation in 50 LGG cases originally classified using the 2007 criteria, including 36 oligoastrocytomas, 11 oligodendrogliomas, 2 astrocytomas, and 1 LGG not otherwise specified. NGS results were compared with those from IHC analysis and fluorescence in situ hybridization to assess concordance and to categorize the tumors according to the 2016 criteria. NGS results were concordant with those from IHC analysis in all cases. In 3 cases, NGS was superior to fluorescence in situ hybridization in distinguishing segmental chromosomal losses from whole-arm deletions. The NGS approach was effective in reclassifying 36 oligoastrocytomas as 30 astrocytomas (20 IDH1/2 mutant and 10 IDH1/2 wild type) and 6 oligodendrogliomas, and 1 oligodendroglioma as an astrocytoma (IDH1/2 mutant). Here we show that a single, targeted NGS assay can serve as the sole testing modality for categorizing LGG according to the World Health Organization's 2016 diagnostic scheme. This modality affords greater accuracy and efficiency while reducing specimen tissue requirements compared with multimodal approaches.

Original languageEnglish (US)
Pages (from-to)328-337
Number of pages10
JournalJournal of Molecular Diagnostics
Volume19
Issue number2
DOIs
StatePublished - Mar 1 2017
Externally publishedYes

Fingerprint

Oligodendroglioma
Central Nervous System Neoplasms
Astrocytoma
Glioma
Fluorescence In Situ Hybridization
Neoplasms
Nucleotides

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine

Cite this

Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas : Application of the World Health Organization's 2016 Revised Criteria for Central Nervous System Tumors. / Carter, Jamal H.; McNulty, Samantha N.; Cimino, Patrick J.; Cottrell, Catherine E.; Heusel, Jonathan W.; Vigh-Conrad, Katinka A.; Duncavage, Eric J.

In: Journal of Molecular Diagnostics, Vol. 19, No. 2, 01.03.2017, p. 328-337.

Research output: Contribution to journalArticle

Carter, Jamal H. ; McNulty, Samantha N. ; Cimino, Patrick J. ; Cottrell, Catherine E. ; Heusel, Jonathan W. ; Vigh-Conrad, Katinka A. ; Duncavage, Eric J. / Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas : Application of the World Health Organization's 2016 Revised Criteria for Central Nervous System Tumors. In: Journal of Molecular Diagnostics. 2017 ; Vol. 19, No. 2. pp. 328-337.
@article{e6fa7df432394618b60abf43b0b099e6,
title = "Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas: Application of the World Health Organization's 2016 Revised Criteria for Central Nervous System Tumors",
abstract = "The 2007 World Health Organization Classification of Tumours of the Central Nervous System classifies lower-grade gliomas [LGGs (grades II to III diffuse gliomas)] morphologically as astrocytomas or oligodendrogliomas, and tumors with unclear ambiguous morphology as oligoastrocytomas. The World Health Organization's newly released (2016) classification incorporates molecular data. A single, targeted next-generation sequencing (NGS) panel was used for detecting single-nucleotide variation and copy number variation in 50 LGG cases originally classified using the 2007 criteria, including 36 oligoastrocytomas, 11 oligodendrogliomas, 2 astrocytomas, and 1 LGG not otherwise specified. NGS results were compared with those from IHC analysis and fluorescence in situ hybridization to assess concordance and to categorize the tumors according to the 2016 criteria. NGS results were concordant with those from IHC analysis in all cases. In 3 cases, NGS was superior to fluorescence in situ hybridization in distinguishing segmental chromosomal losses from whole-arm deletions. The NGS approach was effective in reclassifying 36 oligoastrocytomas as 30 astrocytomas (20 IDH1/2 mutant and 10 IDH1/2 wild type) and 6 oligodendrogliomas, and 1 oligodendroglioma as an astrocytoma (IDH1/2 mutant). Here we show that a single, targeted NGS assay can serve as the sole testing modality for categorizing LGG according to the World Health Organization's 2016 diagnostic scheme. This modality affords greater accuracy and efficiency while reducing specimen tissue requirements compared with multimodal approaches.",
author = "Carter, {Jamal H.} and McNulty, {Samantha N.} and Cimino, {Patrick J.} and Cottrell, {Catherine E.} and Heusel, {Jonathan W.} and Vigh-Conrad, {Katinka A.} and Duncavage, {Eric J.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.jmoldx.2016.10.010",
language = "English (US)",
volume = "19",
pages = "328--337",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "2",

}

TY - JOUR

T1 - Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas

T2 - Application of the World Health Organization's 2016 Revised Criteria for Central Nervous System Tumors

AU - Carter, Jamal H.

AU - McNulty, Samantha N.

AU - Cimino, Patrick J.

AU - Cottrell, Catherine E.

AU - Heusel, Jonathan W.

AU - Vigh-Conrad, Katinka A.

AU - Duncavage, Eric J.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The 2007 World Health Organization Classification of Tumours of the Central Nervous System classifies lower-grade gliomas [LGGs (grades II to III diffuse gliomas)] morphologically as astrocytomas or oligodendrogliomas, and tumors with unclear ambiguous morphology as oligoastrocytomas. The World Health Organization's newly released (2016) classification incorporates molecular data. A single, targeted next-generation sequencing (NGS) panel was used for detecting single-nucleotide variation and copy number variation in 50 LGG cases originally classified using the 2007 criteria, including 36 oligoastrocytomas, 11 oligodendrogliomas, 2 astrocytomas, and 1 LGG not otherwise specified. NGS results were compared with those from IHC analysis and fluorescence in situ hybridization to assess concordance and to categorize the tumors according to the 2016 criteria. NGS results were concordant with those from IHC analysis in all cases. In 3 cases, NGS was superior to fluorescence in situ hybridization in distinguishing segmental chromosomal losses from whole-arm deletions. The NGS approach was effective in reclassifying 36 oligoastrocytomas as 30 astrocytomas (20 IDH1/2 mutant and 10 IDH1/2 wild type) and 6 oligodendrogliomas, and 1 oligodendroglioma as an astrocytoma (IDH1/2 mutant). Here we show that a single, targeted NGS assay can serve as the sole testing modality for categorizing LGG according to the World Health Organization's 2016 diagnostic scheme. This modality affords greater accuracy and efficiency while reducing specimen tissue requirements compared with multimodal approaches.

AB - The 2007 World Health Organization Classification of Tumours of the Central Nervous System classifies lower-grade gliomas [LGGs (grades II to III diffuse gliomas)] morphologically as astrocytomas or oligodendrogliomas, and tumors with unclear ambiguous morphology as oligoastrocytomas. The World Health Organization's newly released (2016) classification incorporates molecular data. A single, targeted next-generation sequencing (NGS) panel was used for detecting single-nucleotide variation and copy number variation in 50 LGG cases originally classified using the 2007 criteria, including 36 oligoastrocytomas, 11 oligodendrogliomas, 2 astrocytomas, and 1 LGG not otherwise specified. NGS results were compared with those from IHC analysis and fluorescence in situ hybridization to assess concordance and to categorize the tumors according to the 2016 criteria. NGS results were concordant with those from IHC analysis in all cases. In 3 cases, NGS was superior to fluorescence in situ hybridization in distinguishing segmental chromosomal losses from whole-arm deletions. The NGS approach was effective in reclassifying 36 oligoastrocytomas as 30 astrocytomas (20 IDH1/2 mutant and 10 IDH1/2 wild type) and 6 oligodendrogliomas, and 1 oligodendroglioma as an astrocytoma (IDH1/2 mutant). Here we show that a single, targeted NGS assay can serve as the sole testing modality for categorizing LGG according to the World Health Organization's 2016 diagnostic scheme. This modality affords greater accuracy and efficiency while reducing specimen tissue requirements compared with multimodal approaches.

UR - http://www.scopus.com/inward/record.url?scp=85012075686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012075686&partnerID=8YFLogxK

U2 - 10.1016/j.jmoldx.2016.10.010

DO - 10.1016/j.jmoldx.2016.10.010

M3 - Article

C2 - 28042970

AN - SCOPUS:85012075686

VL - 19

SP - 328

EP - 337

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 2

ER -